Pain, Agitation/Sedation, Delirium, Immobility, Sleep Disruption, and Neuromuscular Blockade
Zaal IJ, Devlin JW, Hazelbag M, et al. Benzodiazepine-
Med.
2015;41(12):2130-2137.
https://doi.org/10.1007/
s00134-015-4063-z
Zaal IJ, Devlin JW, Peelen LM, Slooter AJ. A system-
atic review of risk factors for delirium in the ICU. Crit
ccm.0000000000000625
Duning T, van den Heuvel I, Dickmann A, et al.
Hypoglycemia
aggravates
critical
illness-induced
neurocognitive
dysfunction.
Diabetes
Care.
2010;33(3):639-644. https://doi.org/10.2337/dc09-1740
Hermans G, Wilmer A, Meersseman W, et al. Impact
of intensive insulin therapy on neuromuscular complica-
tions and ventilator dependency in the medical intensive
489. https://doi.org/10.1164/rccm.200605-665oc
Herridge MS, Cheung AM, Tansey CM, et al. One-year
outcomes in survivors of the acute respiratory distress
syndrome. N Engl J Med. 2003;348(8):683-693. https://
doi.org/10.1056/nejmoa022450
Herridge MS, Tansey CM, Matté A, et al. Functional
disability 5 years after acute respiratory distress syn-
drome. N Engl J Med. 2011;364(14):1293-1304. https://
doi.org/10.1056/nejmoa1011802
Hopkins RO, Suchyta MR, Snow GL, Jephson A,
Weaver LK, Orme JF. Blood glucose dysregulation
and cognitive outcome in ARDS survivors. Brain Inj.
2010;24(12):1478-1484. https://doi.org/10.3109/0269905
2.2010.506861
Jackson JC, Pandharipande PP, Girard TD, et al.
Depression, post-traumatic stress disorder, and func-
tional disability in survivors of critical illness in the
Respir Med. 2014;2(5):369-379. https://doi.org/10.1016/
s2213-2600(14)70051-7
Sevin CM, Bloom SL, Jackson JC, Wang L, Ely EW,
Stollings JL. Comprehensive care of ICU survivors:
development and implementation of an ICU recov-
org/10.1016/j.jcrc.2018.02.011
Stollings JL, Bloom SL, Huggins EL, Grayson SL,
Jackson JC, Sevin CM. Medication management to
ameliorate post-intensive care syndrome. AACN Adv
aacnacc2016931
Stollings JL, Bloom SL, Wang L, Ely EW, Jackson
JC, Sevin CM. Critical care pharmacists and medi-
cation management in an ICU recovery center.
org/10.1177/1060028018759343
Stollings JL, Caylor MM. Postintensive care syndrome
Pharm. 2015;72(15):1315-1323. https://doi.org/10.2146/
ajhp140533
Stollings JL, Poyant JO, Groth CM, et al. An inter-
national, multicenter evaluation of comprehensive
medication management by pharmacists in ICU recov-
https://doi.org/10.1177/08850666231176194
Van den Berghe G, Schoonheydt K, Becx P, Bruyninckx
F, Wouters PJ. Insulin therapy protects the cen-
tral and peripheral nervous system of intensive care
patients. Neurology. 2005;64(8):1348-1353. https://doi.
org/10.1212/01.wnl.0000158442.08857.fc
Neuromuscular Blocking Agents
Greenberg SB, Vender J. The use of neuromuscular
blocking agents in the ICU: where are we now?. Crit
ccm.0b013e31828ce07c
Hraiech S, Dizier S, Papazian L. The use of paralytics in
patients with acute respiratory distress syndrome. Clin
Chest Med. 2014;35(4):753-763. https://doi.org/10.1016/j.
ccm.2014.08.012
Huang DT, Angus DC, Moss M, et al. Design and ratio-
nale of the reevaluation of systemic early neuromuscular
blockade trial for acute respiratory distress syndrome.
org/10.1513/annalsats.201608-629ot
Lagneau F, D’honneur G, Plaud B, et al. A comparison of
two depths of prolonged neuromuscular blockade induced
by cisatracurium in mechanically ventilated critically
https://doi.org/10.1007/s00134-002-1508-y
Murray MJ, DeBlock H, Erstad B, et al. Clinical
practice guidelines for sustained neuromuscular